| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects.
|
Arch Gen Psychiatry
|
2003
|
2.82
|
|
2
|
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
|
Am J Psychiatry
|
2007
|
2.26
|
|
3
|
The cost of relapse and the predictors of relapse in the treatment of schizophrenia.
|
BMC Psychiatry
|
2010
|
1.80
|
|
4
|
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
|
J Clin Psychiatry
|
2007
|
1.73
|
|
5
|
Maintaining informed consent validity during lengthy research protocols.
|
IRB
|
2008
|
1.62
|
|
6
|
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine.
|
J Clin Psychiatry
|
2005
|
1.60
|
|
7
|
Striatal mitochondria in subjects with chronic undifferentiated vs. chronic paranoid schizophrenia.
|
Synapse
|
2011
|
1.43
|
|
8
|
Galantamine for the treatment of cognitive impairments in people with schizophrenia.
|
Am J Psychiatry
|
2007
|
1.39
|
|
9
|
Fluoxetine augmentation of haloperidol in chronic schizophrenia.
|
J Clin Psychopharmacol
|
2003
|
1.37
|
|
10
|
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
|
J Clin Psychiatry
|
2004
|
1.35
|
|
11
|
Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims.
|
Am J Psychiatry
|
2002
|
1.17
|
|
12
|
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia.
|
Clinicoecon Outcomes Res
|
2011
|
1.16
|
|
13
|
Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims.
|
J Psychiatr Res
|
2011
|
1.16
|
|
14
|
Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis.
|
Biol Psychiatry
|
2008
|
1.14
|
|
15
|
Suicide brain is associated with decreased expression of neurotrophins.
|
Biol Psychiatry
|
2005
|
1.13
|
|
16
|
Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims.
|
Int J Neuropsychopharmacol
|
2008
|
1.12
|
|
17
|
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study.
|
J Clin Psychopharmacol
|
2003
|
1.10
|
|
18
|
Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and nondeficit schizophrenia.
|
J Nerv Ment Dis
|
2003
|
1.09
|
|
19
|
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
|
J Clin Psychopharmacol
|
2011
|
1.08
|
|
20
|
Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects.
|
Arch Gen Psychiatry
|
2003
|
1.07
|
|
21
|
The heterogeneity of schizophrenia in disease states.
|
Schizophr Res
|
2004
|
1.04
|
|
22
|
[(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims.
|
Am J Psychiatry
|
2002
|
1.03
|
|
23
|
Postmortem brain tissue of depressed suicides reveals increased Gs alpha localization in lipid raft domains where it is less likely to activate adenylyl cyclase.
|
J Neurosci
|
2008
|
1.01
|
|
24
|
Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide subjects.
|
Biol Psychiatry
|
2010
|
1.00
|
|
25
|
Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.
|
J Clin Psychiatry
|
2010
|
1.00
|
|
26
|
Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits.
|
Biol Psychiatry
|
2004
|
0.99
|
|
27
|
Neurotrophin receptor activation and expression in human postmortem brain: effect of suicide.
|
Biol Psychiatry
|
2008
|
0.99
|
|
28
|
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia.
|
Psychoneuroendocrinology
|
2005
|
0.98
|
|
29
|
Clozapine utilization and outcomes by race in a public mental health system: 1994-2000.
|
J Clin Psychiatry
|
2006
|
0.97
|
|
30
|
Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia.
|
Psychiatr Q
|
2006
|
0.97
|
|
31
|
Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra.
|
Front Psychiatry
|
2012
|
0.95
|
|
32
|
Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: a postmortem brain study.
|
Arch Gen Psychiatry
|
2004
|
0.95
|
|
33
|
Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials.
|
Neuropsychopharmacology
|
2002
|
0.94
|
|
34
|
Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1).
|
Int J Neuropsychopharmacol
|
2009
|
0.94
|
|
35
|
Differential and brain region-specific regulation of Rap-1 and Epac in depressed suicide victims.
|
Arch Gen Psychiatry
|
2006
|
0.94
|
|
36
|
Cyclic AMP response element-binding protein in post-mortem brain of teenage suicide victims: specific decrease in the prefrontal cortex but not the hippocampus.
|
Int J Neuropsychopharmacol
|
2006
|
0.94
|
|
37
|
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.
|
Cost Eff Resour Alloc
|
2009
|
0.93
|
|
38
|
mRNA and protein expression of selective alpha subunits of G proteins are abnormal in prefrontal cortex of suicide victims.
|
Neuropsychopharmacology
|
2002
|
0.93
|
|
39
|
Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression.
|
J Psychiatr Res
|
2003
|
0.92
|
|
40
|
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.
|
J Clin Psychiatry
|
2009
|
0.92
|
|
41
|
Sexuality and schizophrenia: a review.
|
Schizophr Bull
|
2004
|
0.92
|
|
42
|
Clozapine underutilization and discontinuation in African Americans due to leucopenia.
|
Schizophr Bull
|
2006
|
0.92
|
|
43
|
Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjects.
|
Neuropsychopharmacology
|
2007
|
0.91
|
|
44
|
First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.
|
Drugs
|
2005
|
0.91
|
|
45
|
Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims.
|
Neuropsychopharmacology
|
2005
|
0.91
|
|
46
|
Quetiapine at high doses for the treatment of refractory schizophrenia.
|
Schizophr Res
|
2008
|
0.90
|
|
47
|
Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death.
|
J Psychiatr Res
|
2004
|
0.90
|
|
48
|
Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia.
|
Am J Med Genet B Neuropsychiatr Genet
|
2009
|
0.90
|
|
49
|
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.
|
Schizophr Res
|
2011
|
0.89
|
|
50
|
Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study.
|
J Clin Psychiatry
|
2006
|
0.88
|
|
51
|
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
|
Stat Med
|
2005
|
0.88
|
|
52
|
Synaptic differences in the postmortem striatum of subjects with schizophrenia: a stereological ultrastructural analysis.
|
Synapse
|
2005
|
0.88
|
|
53
|
Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response.
|
Synapse
|
2009
|
0.87
|
|
54
|
Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients.
|
Bipolar Disord
|
2008
|
0.87
|
|
55
|
Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
|
Compr Psychiatry
|
2009
|
0.86
|
|
56
|
Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
|
Schizophr Res
|
2008
|
0.85
|
|
57
|
Atypical antipsychotic use in a state hospital inpatient adolescent population.
|
J Child Adolesc Psychopharmacol
|
2004
|
0.85
|
|
58
|
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.
|
J Clin Psychiatry
|
2011
|
0.85
|
|
59
|
Fatty acid composition of the postmortem prefrontal cortex of adolescent male and female suicide victims.
|
Prostaglandins Leukot Essent Fatty Acids
|
2008
|
0.85
|
|
60
|
Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.
|
Neuropsychiatr Dis Treat
|
2012
|
0.84
|
|
61
|
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
|
Curr Med Res Opin
|
2011
|
0.84
|
|
62
|
5-Lipoxygenase in the Prefrontal Cortex of Suicide Victims.
|
Open Neuropsychopharmacol J
|
2008
|
0.84
|
|
63
|
Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response.
|
Synapse
|
2011
|
0.83
|
|
64
|
Circumstances of suicide among individuals with schizophrenia.
|
Schizophr Res
|
2002
|
0.83
|
|
65
|
Differential synaptic changes in the striatum of subjects with undifferentiated versus paranoid schizophrenia.
|
Synapse
|
2008
|
0.83
|
|
66
|
Mitochondria in the striatum of subjects with schizophrenia.
|
World J Biol Psychiatry
|
2010
|
0.83
|
|
67
|
Reaching for wellness in schizophrenia.
|
Psychiatr Clin North Am
|
2007
|
0.83
|
|
68
|
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine.
|
Neuropsychopharmacology
|
2010
|
0.83
|
|
69
|
GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicide.
|
Neurochem Res
|
2008
|
0.83
|
|
70
|
Plasma concentrations of high-dose olanzapine in a double-blind crossover study.
|
Hum Psychopharmacol
|
2006
|
0.83
|
|
71
|
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
|
BMC Psychiatry
|
2011
|
0.82
|
|
72
|
Aberrant extracellular signal-regulated kinase (ERK) 5 signaling in hippocampus of suicide subjects.
|
Neuropsychopharmacology
|
2007
|
0.81
|
|
73
|
Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia.
|
Ann Clin Psychiatry
|
2004
|
0.81
|
|
74
|
Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics.
|
J Clin Psychiatry
|
2004
|
0.80
|
|
75
|
Deaths from diabetic ketoacidosis after long-term clozapine treatment.
|
Am J Psychiatry
|
2003
|
0.80
|
|
76
|
Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone.
|
Clin Neuropharmacol
|
2003
|
0.80
|
|
77
|
Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
|
Schizophr Res
|
2011
|
0.80
|
|
78
|
Researcher experiences with IRBs: a survey of members of the American College of Neuropsychopharmacology.
|
IRB
|
2011
|
0.79
|
|
79
|
Perception of depot antipsychotics by mental health professionals.
|
J Psychiatr Pract
|
2003
|
0.79
|
|
80
|
Clozapine treatment in patients with prior substance abuse.
|
Can J Psychiatry
|
2003
|
0.79
|
|
81
|
Synaptic differences in the patch matrix compartments of subjects with schizophrenia: a postmortem ultrastructural study of the striatum.
|
Neurobiol Dis
|
2005
|
0.79
|
|
82
|
Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.
|
Ann Clin Psychiatry
|
2008
|
0.78
|
|
83
|
Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis.
|
J Clin Psychopharmacol
|
2004
|
0.78
|
|
84
|
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
|
J Clin Psychiatry
|
2012
|
0.76
|
|
85
|
Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia.
|
J Neuropsychiatry Clin Neurosci
|
2005
|
0.76
|
|
86
|
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials.
|
J Clin Psychopharmacol
|
2010
|
0.76
|
|
87
|
Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
|
J Med Econ
|
2012
|
0.76
|
|
88
|
Challenge to atypical antipsychotic drug effect on cognition.
|
Am J Psychiatry
|
2007
|
0.76
|
|
89
|
The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia.
|
J Clin Psychopharmacol
|
2005
|
0.76
|
|
90
|
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
|
J Clin Psychiatry
|
2003
|
0.76
|
|
91
|
Evaluating sexual function in patients with treatment-resistant schizophrenia.
|
Schizophr Res
|
2003
|
0.76
|
|
92
|
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
|
J Clin Psychopharmacol
|
2013
|
0.75
|
|
93
|
Comparison of clozapine response for inpatients in the research setting versus routine clinical practice.
|
Psychiatr Q
|
2008
|
0.75
|
|
94
|
Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics.
|
J Clin Psychiatry
|
2009
|
0.75
|
|
95
|
Protecting confidentiality in human research.
|
Am J Psychiatry
|
2013
|
0.75
|
|
96
|
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
|
J Clin Psychopharmacol
|
2007
|
0.75
|
|
97
|
Cortisol response to buspirone in extended abstinent alcoholics.
|
Alcohol Alcohol
|
2004
|
0.75
|
|
98
|
Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study.
|
CNS Spectr
|
2006
|
0.75
|